CorMedix Set for Breakout with DefenCath's Outpatient Launch
AI Prediction of CorMedix Inc. (CRMD)
CorMedix, a biopharmaceutical company focused on developing and commercializing therapeutic products, shows promise with its lead product, DefenCath. Recent FDA approval and subsequent commercial launch plans indicate potential growth. The upcoming PDUFA date and commercial roll-out in outpatient settings could serve as significant catalysts, impacting the stock positively.
CRMD Report Information
Prediction Date2025-07-03
Close @ Prediction$11.62
Mkt Cap680m
IPO DateN/a
AI-derived Information
Recent News for CRMD
- Jun 8, 8:30 am — U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation (GlobeNewswire RSS)
- May 15, 8:30 am — Cormedix Therapeutics to Participate in two Upcoming Investor Conferences (GlobeNewswire)
- May 14, 7:02 pm — Cormedix Inc (CRMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
- May 14, 4:45 pm — CorMedix Inc. Q1 2026 Earnings Call Summary (Moby)
- May 14, 10:06 am — CorMedix Shares Jump After Revenue Beat and Higher Full-Year Guidance (InvestorsHub)
- May 14, 7:37 am — CorMedix: Q1 Earnings Snapshot (Associated Press)
- May 14, 7:30 am — Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
- May 5, 8:30 am — CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026 (GlobeNewswire)
- Apr 27, 7:30 am — CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients (GlobeNewswire)
- Apr 7, 8:30 am — CorMedix to Participate in Needham Virtual Healthcare Conference (GlobeNewswire)
- Mar 6, 8:30 am — CorMedix Inc. Q4 2025 Earnings Call Summary (Moby)
- Mar 5, 8:18 pm — CorMedix Q4 Earnings Call Highlights (MarketBeat)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.